Who Needs Monitoring for Tysabri-Related PML? Risk Factors to Review

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health to Occupational Exposure: The Context of Tysabri in Mass Production

If you or a loved one is on Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early symptoms like confusion or vision changes is critical. Decades of pharmacovigilance have established a clear link between Tysabri and PML, with risk factors including JC virus antibody status, treatment duration, and prior immunosuppressant use. This page reviews the FDA label context, symptom timeline, and documentation essentials to help you stay informed.

Medical Evidence Linking Tysabri to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, as the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits such as weakness, cognitive decline, visual disturbances, or coordination problems. Diagnosis is confirmed through MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The clinical course is often devastating, with the label noting that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and understanding of risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Mechanisms of Tysabri-Associated PML

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning and prescribing information clearly state the increased risk and identify specific risk factors. However, questions may arise about whether patients were adequately informed of these risks before treatment, particularly given the severity of PML. For affected patients in Virginia, settlement-related considerations depend on the timeline between exposure and documented harm. The statute of limitations for personal injury claims in Virginia is generally two years from the date the injury was discovered or should have been discovered. Given that PML symptoms can develop months to years after starting Tysabri, the clock may start when a patient first experiences neurological symptoms or receives a PML diagnosis. Patients should consult with a legal professional to determine how this applies to their specific case. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JC virus to reactivate and cause PML in susceptible individuals. The label notes that PML "typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and Tysabri's mechanism creates a state of localized immunosuppression in the brain. For patients pursuing settlement, documentation of the timeline is essential. This includes the date Tysabri was started, the duration of therapy, any prior immunosuppressant use, and the date of PML diagnosis. The presence of anti-JCV antibodies should also be documented, as this is a known risk factor. The label emphasizes that "patients who are anti-JCV antibody positive have a higher risk for developing PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri Claims in Virginia

In summary, the medical evidence clearly establishes that Tysabri increases PML risk, with identifiable risk factors and a requirement for monitoring. For Virginia patients, the statute of limitations for filing a claim related to Tysabri-associated PML is typically two years from discovery of the injury. Settlement considerations should account for the severity of PML, the adequacy of warnings provided, and the specific timeline of exposure and harm. Patients are advised to seek both medical and legal counsel to navigate these complex issues.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or should have been discovered. Given that PML symptoms may develop months to years after starting Tysabri, the clock typically starts when a patient first experiences neurological symptoms or receives a PML diagnosis. It is crucial to consult with a legal professional to determine the specific timeline for your case.

What are the key risk factors for developing PML while on Tysabri?

The prescribing information for Tysabri identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer therapy. These factors should be carefully considered when initiating or continuing Tysabri treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.